With the help of Stallergenes Greer products and services

Stallergenes Greer is here to facilitate allergy immunotherapy (AIT) treatment in your office. We offer a broad portfolio of AIT extracts, as well as prescription services through GREER® Pharmacy, that provide custom patient formulations mixed by our pharmacy staff.


Extracts and Supplies for offices that formulate on their own

We offer a broad range of treatment products for practices interested in mixing

Stallergenes Greer also offers a sublingual grass allergy immunotherapy tablet treatment option. Learn more.


Please see Important Safety Information for GREER® ExtractsTM below.
Please click here for Package Inserts with full Prescribing Information, including Boxed Warnings.

Offering AIT Formulation Services Through GREER® Pharmacy

Using our expert pharmacy staff and quality extracts, GREER® Pharmacy specializes in preparing all types of allergy immunotherapy formulations, from the simple to the complex.

For more information about GREER® Pharmacy services or to speak to a Customer Care Specialist, call 800.378.3906 or email

*Allergenic extracts are manufactured by either Greer Laboratories, Inc or AllerMed.

Back to top


Allergenic extracts are indicated for skin test diagnosis and treatment (immunotherapy) of patients with seasonal and perennial allergies.

See the package inserts for the full Prescribing Information for the specific extracts.


  • Do not inject intravenously.
  • Do not administer these products to patients with severe, unstable, or uncontrolled asthma.
  • Allergenic extracts may cause severe life-threatening systemic reactions, including the rare occurrence of anaphylaxis or death. Systemic reactions include: generalized skin erythema, urticaria, pruritus, angioedema, rhinitis, wheezing, laryngeal edema, and hypotension. Other adverse reactions include: nausea, emesis, abdominal cramps, and diarrhea.
  • Intended for use only by physicians who are experienced in the administration of allergenic extracts.
  • Observe patients in the office for at least 30 minutes following treatment. Emergency measures and personnel trained in their use must be available immediately in the event of a life-threatening reaction.
  • Patients with extreme sensitivity to these products, those on an accelerated immunotherapy build-up schedule, those switching to another allergenic lot, those receiving high doses of these products, or those also exposed to similar allergens may be at increased risk of a severe allergic reaction.
  • Immunotherapy may not be suitable for patients with medical conditions that reduce their ability to survive a severe allergic reaction.
  • These products may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers.

Please click here for Package Inserts with full Prescribing Information, including Boxed Warnings.

To report suspected adverse reactions, contact Stallergenes Greer at 1-855-274-1322 or FDA at 1-800-FDA-1088 or